REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-08

Reporting Person: STAHL NEIL (EVP Research and Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-08	Common Stock	A	2926	$0.0	Acquired	53883	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Non-Qualified Stock Option (right to buy)	$644.54	A	12494	Acquired	2031-12-08	Common Stock (12494)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5792	Indirect
Common Stock	4605	Indirect

Footnotes

F1: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.